|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.64 USD | -0.42% |
|
-2.46% | -19.52% |
| Apr. 11 | North American Morning Briefing : Stock Futures -2- | DJ |
| Apr. 10 | Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform | MT |
March 22 (Reuters) - A panel of U.S. Food and Drug Administration (FDA) advisers on Wednesday voted against the effectiveness of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS). (Reporting by Bhanvi Satija and Raghav Mahobe in Bengaluru; Editing by Shounak Dasgupta)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 193.3 USD | +1.45% | -2.33% | 27.69B | ||
| 40.64 USD | -0.42% | -2.46% | 5.95B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -19.52% | 5.95B | |
| -1.49% | 41.35B | |
| +42.15% | 40.38B | |
| +1.44% | 39.05B | |
| -14.19% | 26.67B | |
| +2.01% | 24.07B | |
| -24.61% | 18.36B | |
| -4.04% | 11.68B | |
| +21.21% | 11.6B | |
| +7.80% | 11.15B |
IONIS PHARMACEUTICALS, INC. 
